BLOOD CLOTTING FACTORS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Blood Clotting Factors Market - Overview Blood Clotting Factors Market, by Product Type (Factors VII, Factor VIII, Factor IX, Factor X, Factor XIII, Von Willebrand Factor, Anti-Inhibitor Coagulant Complex, and Others), By Application (Haemophilia, Von Willebrand Disease, Surgery, and Other Bleeding Disorders), By Technology (Plasma-derived and Recombinant), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Blood clotting factors are proteins or enzymes that control bleeding. Blood clotting or blood coagulation is a process in which blood gets converted into solid clots at time of any wound or break down of blood vessels. Clotting can prevent death from bleeding and also restrict the entry of bacteria and viruses into the body. Haemostasis is the mechanism for blood clotting, which in controlled by a number of factors called blood clotting factors. Deficiency of these factors can cause blood clotting diseases such as haemophilia and von willebrand disease (VWD). According to Centre for disease control and prevention (CDC), 2017, around 20,000 males were suffering from Hemophilia in the U.S. Approval of novel drugs is expected to propel the market growth over the forecast period. For instance, in Janauary 2020, CSL Behring received Korea Ministry of Food and Drug Safety approval for Afstyla, a single-chain recombinant antihemophilic factor VIII therapy indicated for patients suffering from Hemophilia A. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing-insight/bloodclotting-factors-market-1301 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency). Further, in July 2019, Novo Nordisk received the Health Canada approved for Esperoct indicated for the treatment of patients with Hemophilia A. High prevalence of Hemophilia is expected to drive the growth of the Blood Clotting Factor market. According to the data published by the Centers for Disease Control and Prevention (CDC) in September 2018, Hemophilia A affected 1 in 5,000 male births in the U.S. Similarly, according to the data published by Cleveland Clinic, in 2016, Hemophilia affected around 1 in 25,000 to 30,000 males. According to National Hemophilia Foundation 2018 report, one in 10,000 people are born with hemophilia A due to deficiency of clotting factor VIII and one in 50,000 people are born with hemophilia B due to lack of clotting factor IX Rising initiatives and donation for supporting the patients diagnosed with Hemophilia is expected to propel the market growth over the forecast period. For instance, in April 2019, Grifols International SA a provider of plasma derived products, donated more than 100 million international units of blood clotting factor drugs under the long term initiative of providing support to the Hemophilia patients. Due to such policy, the company has invested in rare disease research which has led to development of products such as Hemlibra (Emicizumab-kxwh), Adynovate and Others. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/1301 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Furthermore, rising number of product approvals and increasing awareness regarding rare disease in developed economies such as U.S. and Canada has resulted in high number of patients receiving treatment. Owing to above mentioned factors, North America has dominated the market and it is also expected to retain position over the forecast period. For instance, in February, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval for Turoctocog alfa pegol also called as N8-GP (Esperoct), a long acting factor VIII replacement treatment for adults and children suffering from hemophilia A. Asia Pacific is expected to witness robust growth in the market due to increasing number of patients suffering from disease, favorable reimbursement policy and rising product launch by the market players. For instance, in April 2019, Roche Products India Pvt. Ltd launched its hemophilia A drug, Emicizumab, branded as Hemlibra, in India. It is indicated as a prophylactic treatment for reducing frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors. According to the Chinese Ministry of Health report 2012, in China, outpatient hemophilia treatment is covered by health insurance schemes in more than 80% of the cities in China, with reimbursement caps and patient co-pay requirements more than 50%. Buy-Now this Research Report @
https://www.coherentmarketinsights.com/insight/buy-now/1301 Š Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
Š Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
Š Coherent market Insights. All Rights Reserved